MarketPeel
Insider Trading Intelligence
Pricing
…
SM

Sean F. Moran

CRBP
CHIEF FINANCIAL OFFICER · CORBUS PHARMACEUTICALS HOLDINGS, INC. · CIK 0001451495
FILING MIX · LIFETIME54%/46%
BUYS
22
SELLS
19
TOTAL VALUE
$2.14M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
96,694
AVG SELL PX
$4.07
TRADE KIND
SHOWING 41 / 41
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Sean F. Moran, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+76.92%-5.92%+0.46%-6.38%-2.98%—
14d13+69.23%-3.95%+0.70%-4.65%-8.73%—
30d13+23.08%+7.99%+0.45%+7.54%+14.23%—
60d13+23.08%+19.72%-0.71%+20.43%+5.56%—
90d13+15.38%+9.54%+2.85%+6.68%-0.38%—
180d13(1 pending)+41.67%-24.65%+7.85%-32.51%-42.12%—
1y13(2 pending)+81.82%-52.41%+12.89%-65.30%-80.10%—
2y13(3 pending)+100.00%+71.85%+25.82%+46.03%-99.61%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRBP · 96,694 shares · as of Feb 13, 2026
0233,661467,323700,984934,645202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 22 buys / 19 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
4,701$7.78$36.6K96,694Feb 13, 2026Feb 18, 2026 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
28,082——101,395Jan 14, 2026Jan 16, 2026 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
84,247——84,247Jan 14, 2026Jan 16, 2026 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
12,981$17.02$220.9K73,313Oct 24, 2025Oct 27, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
12,981——10,386Oct 24, 2025Oct 27, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
12,981$4.26$55.3K86,294Oct 24, 2025Oct 27, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
2,792$8.76$24.4K73,313Feb 14, 2025Feb 18, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
92,500——92,500Jan 31, 2025Feb 4, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
27,500——76,105Jan 31, 2025Feb 4, 2025 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
1,958$30.00$58.7K50,563Jun 18, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
1,958——0Jun 18, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
1,958$42.12$82.5K48,605Jun 18, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
6,730$46.77$314.8K48,605Jun 17, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
6,730——11,217Jun 17, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
6,730$14.10$94.9K55,335Jun 17, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
7,788$4.26$33.2K56,393Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
1,567$49.87$78.2K48,605Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
7,788$49.87$388.4K48,605Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
1,567$30.00$47.0K50,172Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
7,788——23,367Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
1,567——1,958Jun 14, 2024Jun 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
1,787$30.00$53.6K48,605Apr 10, 2024Apr 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
1,787——0Apr 10, 2024Apr 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
40,176——40,176Feb 12, 2024Feb 14, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
40,176——46,818Feb 12, 2024Feb 14, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
934,645——934,645Feb 13, 2023Feb 15, 2023 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
20,000$0.26$5.2K199,272Aug 10, 2022Aug 10, 2022 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
12,000$0.30$3.6K179,272May 16, 2022May 16, 2022 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
15,000$0.37$5.5K167,272Mar 10, 2022Mar 10, 2022 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
538,400——538,400Feb 1, 2022Feb 4, 2021 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
307,300——307,300Feb 2, 2021Feb 4, 2021 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
87,500$1.40$122.5K87,500Dec 21, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
87,500$1.40$122.5K437,110Dec 21, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
87,500$1.75$153.1K349,610Dec 21, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
53,610$1.00$53.6K53,610Dec 18, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
53,610$1.40$75.1K349,610Dec 18, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
53,610$1.00$53.6K403,220Dec 18, 2020Dec 22, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
36,923$1.32$48.6K349,610Dec 16, 2020Dec 18, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
Chief Financial Officer
36,923$0.17$6.1K386,533Dec 16, 2020Dec 18, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
Chief Financial Officer
36,923$0.17$6.1K36,923Dec 16, 2020Dec 18, 2020 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASEGRANT
Stock grant
226,000——226,000Mar 6, 2020Mar 9, 2020 ↗View →
Other insiders · CRBP
Loading peer insiders…
About this filer
CIK 0001451495
ROLE
Chief Financial Officer
PRIMARY
CRBP
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001451495DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback